{"version":"1.0","provider_name":"Centro Atl\u00e1ntico del Medicamento, S.A.","provider_url":"https:\/\/ceamedsa.com\/en\/","author_name":"admin","author_url":"https:\/\/ceamedsa.com\/en\/author\/admin\/","title":"CEAMED's proposal for COVID-19 - Centro Atl\u00e1ntico del Medicamento, S.A.","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"sn1LIp641L\"><a href=\"https:\/\/ceamedsa.com\/en\/ceameds-proposal-for-covid-19\/\">CEAMED&#8217;s proposal for COVID-19<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/ceamedsa.com\/en\/ceameds-proposal-for-covid-19\/embed\/#?secret=sn1LIp641L\" width=\"600\" height=\"338\" title=\"&#8220;CEAMED&#8217;s proposal for COVID-19&#8221; &#8212; Centro Atl\u00e1ntico del Medicamento, S.A.\" data-secret=\"sn1LIp641L\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/ceamedsa.com\/wp-includes\/js\/wp-embed.min.js\n\/* ]]> *\/\n<\/script>\n","description":"CEAMED has been developing small molecule inhibitors of STAT3 as possible treatments for Triple Negative Breast Cancers (TNBCs), whose development and metastasis are believed to be driven by STAT3 activation. CEAMED has various families of compounds that reduce the levels of IL-6 activated STAT3, with cellular IC50 values between 50 y 1000 nM (for comparison &hellip; Continue reading \"\"","thumbnail_url":"https:\/\/ceamedsa.com\/wp-content\/uploads\/2020\/07\/inhibition-STAT3-CEAMED-compounds.png"}